https://doi.org/ 10.33472/AFJBS.6.9.2024.2349-2379

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Molecular Farming: Biotechnological Approaches for Producing High-Value Plant-derived Pharmaceuticals

Dr.R.Roghini,
Senior Research Scientist, Central Research Lab ACS medical College and Hospital Vellapanchavadi, Chennai 73
Dr. Amit Kumar Dutta,
Amity Institute of Biotechnology, Amity University, Jharkhand, Ranchi.
Dr Ram Babu,
Associate professor Department of Botany, Kirori Mal College North Campus, University of Delhi Delhi 110007
Dr.Devidas Narhar Patil,
Head and Assoc.Prof., Department of Botany BJS, Arts Science and Commerce College, Wagholi, Pune-412207.
Dr. A. Nirmala
Associate professor Department of biotechnology Aarupadai Veedu Institute of Technology Vinayaka Missions Research Foundation Paiyanoor-603 104, Tamil Nadu, India

Article History
Volume 6,Issue 9, 2024
Received: 26-03-2024
Accepted : 30-04-2024
doi: 10.33472/AFJBS.6.9.2024.2349-2379

Abstract: Molecular farming is a biotechnological method that involves using genetically modified plants to produce valuable medications. It has gained recognition as a revolutionary technique in the field. This novel approach utilizes the biosynthetic capacities of plants to generate intricate biomolecules, providing a scalable and cost-efficient substitute for conventional pharmaceutical manufacturing. This study article explores the several biotechnology methods used in molecular farming, focusing on the progress, difficulties, and future potential of this area.

Plants, with their ability to produce a wide range of secondary metabolites, offer a distinct opportunity for the creation of medications. Molecular farming exploits the inherent inclination of plants by inserting targeted genes to generate recombinant proteins, antibodies, vaccines, and other medicinal substances. Extensive research has been conducted on the utilisation of several plants,

including tobacco, maize, rice, and mosses. Each of these plants has unique benefits in terms of their ability to thrive in specific environmental circumstances, produce a large amount of biomass, and undergo post-translational alterations.

Transgenic plants are a key biotechnology method used in molecular farming. This method involves the incorporation of foreign genes into the genetic material of the plant, allowing the plant to produce the necessary medicinal proteins. Agrobacterium-mediated transformation and biolistic particle administration are frequently employed techniques for gene insertion. Agrobacterium-mediated transformation utilises the inherent capability of Agrobacterium tumefaciens to transfer DNA into plant cells, whereas biolistic particle delivery, sometimes referred to as the gene gun approach, includes the physical injection of DNA-coated particles into plant tissues.

Transient expression systems offer a viable method for quickly producing medications without the requirement of stable genetic integration. This approach frequently utilises viral vectors or agroinfiltration techniques, enabling rapid and abundant protein expression. Transient systems offer significant benefits for the rapid production of vaccines in response to newly emerging diseases, where time is of utmost importance.

Efficiently regulating gene expression is a crucial component of molecular farming. This involves choosing robust promoters, enhancers, and terminators to stimulate transcription at a high level, as well as optimising codons to improve translation efficiency in plant cells. In addition, directing recombinant proteins to certain organelles, such as the endoplasmic reticulum or chloroplasts, can enhance protein stability and increase protein accumulation.

The complexity of plant tissues and the existence of plant-specific pollutants make downstream processing and purification of plant-derived medications difficult. The implementation of purification techniques, such as affinity chromatography and the utilisation of plant-specific tags, has resulted in enhanced production efficiency and purity of the end product. Furthermore, the inclusion of regulatory factors and the implementation of stringent manufacturing standards (GMP) are crucial in guaranteeing the safety and effectiveness of medications generated from plants.

Molecular farming has extensive potential applications, including the generation of monoclonal antibodies, medicinal enzymes, and vaccine antigens. Significant achievements include the creation of ZMapp, a combination of monoclonal antibodies utilised in the treatment of Ebola virus, as well as the formulation of plant-derived vaccines for influenza and norovirus. These examples highlight the potential of molecular farming to tackle global health concerns.

Although molecular farming holds great potential, it encounters various obstacles. The commercial viability of plant-derived medications is heavily influenced by three essential factors: public perception and acceptance of genetically modified organisms (GMOs), intellectual property difficulties, and the necessity for stringent regulatory frameworks. Furthermore, the potential of

molecular farming systems to be scaled up and the economic viability of production are still subjects of continuing investigation.

To summarise, molecular farming is a groundbreaking method in the biotechnological manufacturing of medications. This technology utilises the innate capacities of plants to create a sustainable and adaptable system for manufacturing valuable medicinal chemicals. Ongoing progress in genetic engineering, optimisation of expression, and purification methods is anticipated to surpass existing constraints, therefore facilitating the mainstream acceptance of medications generated from plants. Molecular farming has the potential to greatly impact world healthcare by offering accessible and affordable cures for various ailments as the science advances.

Keywords: *Molecular Farming, Biotechnological Approaches, Plant-derived Pharmaceuticals, Recombinant Proteins, Genetic Engineering, Transgenic Plants, Agrobacterium-mediated Transformation, Transient Expression Systems, Downstream Processing, Vaccine Production.*

1. Introduction:

Molecular farming is a growing subject that combines plant biotechnology and pharmaceutical manufacture (1). It has gained considerable attention because of its potential to transform the creation of valuable therapeutic chemicals. This novel strategy utilises genetically modified plants as bioreactors to manufacture medications, providing an alternative to conventional manufacturing methods that depend on microbial or mammalian cell cultures (2). The emergence of molecular farming signifies a significant change in the production of biopharmaceuticals, motivated by the requirement for scalable, cost-efficient, and environmentally friendly solutions to address the increasing worldwide need for medical treatments (3).

The practice of using plants to produce therapeutic proteins originated in the early 1990s, when the first genetically modified tobacco and potato plants effectively generated recombinant proteins (4). Subsequently, the discipline has undergone rapid evolution, characterised by breakthroughs in genetic engineering techniques, expression systems, and downstream processing technologies. Plants provide various inherent benefits as production platforms, such as the capacity to carry out intricate post-translational alterations, minimal risk of contamination with human diseases, and the possibility of large-scale growing in open fields or controlled conditions.

Choosing appropriate plant species is a crucial factor in molecular farming (5). Widely utilised plants comprise tobacco (Nicotiana tabacum), maize (Zea mays), rice (Oryza sativa), and mosses (Physcomitrella patens), each providing distinct advantages. Tobacco is preferred for its abundant biomass production and recognised methods of modification, while maize and rice are advantageous since they are widely consumed crops, making it easier to incorporate them into existing agricultural systems (6). In contrast, mosses offer a steady and manageable setting for protein production, exhibiting little variations in glycosylation as compared to human proteins (7).

In molecular farming, genetic engineering commonly entails the incorporation of specific genes that encode therapeutic proteins into the genetic makeup of plants (8). The permanent incorporation of the foreign gene can be accomplished by stable transformation methods, such as Agrobacterium-mediated transformation or biolistic particle delivery. Transient expression systems, which do not entail genome integration, have become popular because they can rapidly produce recombinant proteins at high quantities (9). These methods commonly employ viral vectors or agroinfiltration techniques to introduce the desired genes.

Maximising the production and functioning of recombinant proteins requires the optimisation of gene expression (10). Strategies involve employing robust constitutive or tissue-specific promoters, optimising codons to facilitate translation, and targeting specific subcellular locations to optimise protein stability and accumulation. Moreover, the selection of promoters and enhancers is essential in promoting strong expression, whereas terminators guarantee effective termination of transcription and stability of the mRNA (11).

Plant-derived pharmaceutical production involves the manufacturing of various medicinal proteins, such as monoclonal antibodies, vaccines, and enzymes (12). Prominent instances encompass ZMapp, a combination of monoclonal antibodies employed for the therapy of Ebola virus, as well as diverse plant-derived vaccines developed for ailments including influenza and norovirus. These success stories demonstrate the capacity of molecular farming to effectively tackle pressing health issues by providing timely and cost-efficient solutions (13).
In spite of its optimistic prospects, molecular farming encounters certain obstacles that need to be resolved in order to attain economic feasibility (14). These factors encompass the way the general public views and the obstacles imposed by regulations on genetically modified organisms (GMOs), the intricacy of subsequent processing and purification, and the capacity to expand production systems. To acquire public trust and regulatory approval for plant-derived medications, it is crucial to adhere to good manufacturing standards (GMP) and build strong regulatory frameworks (15).
This study paper seeks to present a thorough and detailed examination of the present condition of molecular farming, including an analysis of the biotechnological methods employed, the progress achieved, and the obstacles faced (16). Through an examination of the possible uses and future paths of this area, we aim to emphasise the profound influence of molecular farming on the manufacturing of pharmaceuticals and worldwide healthcare. Molecular farming, achieved through ongoing research and collaboration, offers the potential to provide cost-effective and easily obtainable therapeutic solutions to cater to the need of various global populations (17).

2. Plant Systems Used in Molecular Farming:

Molecular farming utilises plants as bioreactors to produce valuable drugs (18). The choice of plant systems is essential for maximising yield, scalability, and cost-efficiency. This section examines the many plant species that are frequently utilised in molecular farming, along with the criteria used to pick them, and the benefits and constraints associated with each system.

2.1 Criteria for Selecting Plant Species

The selection of plant species for molecular farming is contingent upon various factors:

- Biomass Yield: Plants with high biomass production are desirable since they can generate a greater quantity of raw material for pharmaceutical extraction.

- Optimal Growing settings: Plants that may be readily cultivated under regulated settings or in open areas are beneficial (19).

- Genetic Transformation Efficiency: It is desirable to work with species that can be genetically manipulated and can effectively express foreign genes in a stable manner (20).

- Post-Translational Modifications: Plants that have the ability to carry out post-translational modifications similar to humans play a crucial role in ensuring the correct folding and functioning of recombinant proteins (21).

- Regulatory Acceptance: Species that have a proven track record of being safe for use in agriculture and eating are more likely to receive permission from regulatory authorities (22).

2.2 Plants that are frequently utilised

Tobacco (Nicotiana tabacum):

Advantages: -

- Exhibits high biomass output and demonstrates quick growth.

- Established genetic transformation protocols.

- Elevated levels of recombinant protein expression.

Disadvantages: -

- The presence of nicotine and other alkaloids can make the purifying process more complex (23).

- Public perception challenges arise as a result of its affiliation with smoking.

Maize (Zea mays):

Advantages:-

- Well-developed agricultural practices and infrastructure.

- The production of a large amount of biomass and the ability to increase production on a larger scale (24).

- Capacity to generate substantial volumes of medications derived from seeds.

Disadvantages: -

- Lengthy maturation period in comparison to certain other plant species.

- Regulatory issues pertaining to genetically modified (GM) crops.

Rice (Oryza sativa): -

Advantages: -

- Extensively grown essential crop with established agricultural systems.

- Thoroughly researched genetic makeup and techniques for altering it (25).

- Possibility of cultivating medications through seed-based manufacture for long-term stability.

Limitations: -

- Extended duration of growth cycle and possibility of contamination with food supplies.

- Involves the use of complex procedures to eliminate starches during the later stages of processing.

Mosses (Physcomitrella patens): -

Advantages: -

- Mosses, specifically the species Physcomitrella patens, offer a straightforward and consistent genetic system that allows for efficient homologous recombination (26).

- Capability to execute glycosylation processes that resemble those performed by humans. Regulating growth conditions within bioreactors.

Limitations: -

- Lower biomass productivity in comparison to higher plants.

- Production systems are not as well-developed and necessitate specialised facilities.

2.3 Benefits and Constraints of Each Plant System

Every plant system provides distinct advantages and encounters various obstacles. Tobacco is preferred due to its fast growth and high biomass production, which makes it well-suited for the

large-scale production of recombinant proteins (27). Nevertheless, the existence of poisonous alkaloids requires rigorous purification procedures. Maize and rice are beneficial because they are staple crops that may readily be incorporated into current agricultural systems. Their seed-based production processes provide enduring stability for pharmaceuticals, despite the considerable constraints posed by regulatory obstacles and the risk for contamination with food supplies.

Mosses offer a hopeful alternative because to their capacity to carry out post-translational alterations similar to humans and possess stable genetic systems (28). Bioreactors provide exact manipulation of environmental parameters, hence ensuring consistent output during their growth. Nevertheless, the reduced biomass productivity and the requirement for specialised cultivating facilities may restrict their capacity to be scaled up.

3. Genetic Engineering Techniques:

Genetic engineering plays a crucial role in molecular farming by allowing the incorporation of genes that code for specific medicinal proteins into the genomes of plants (29). This section provides an overview of the main genetic engineering techniques employed in molecular farming, which encompass stable transformation approaches and transient expression systems.

3.1 Methods for achieving stable transformations

Stable transformation refers to the process of incorporating foreign genes into the genetic makeup of a plant, which enables the plant to pass on the production of modified proteins to future generations. Agrobacterium-mediated transformation and biolistic particle delivery are two commonly employed strategies for steady transformation.

3.2 Agrobacterium-mediated transformation

Agrobacterium-mediated transformation is a process where DNA is transferred from the soil bacterium Agrobacterium tumefaciens to plant cells, utilising the bacterium's natural capacity to transfer genes. This procedure encompasses multiple crucial stages:

1. Gene Construct Preparation: The gene of interest is incorporated into a T-DNA section of a Ti plasmid, together with essential regulatory components including promoters and terminators (30).

2. Infection: The recombinant Ti plasmid is inserted into Agrobacterium tumefaciens, which is subsequently employed to invade plant tissues, usually leaf discs or callus cultures.

3. Integration and Regeneration: The T-DNA, which contains the desired gene, is introduced into the genome of the plant. The cells that have undergone transformation are carefully chosen and then developed into complete plants by a process of regeneration (31).

Advantages: -

Dicotyledonous plants (dicots) such as tobacco and potato exhibit high efficiency. - The technique is relatively easy and cost-effective.

The transgene is integrated in a stable and heritable manner.

Disadvantages : -

Reduced efficacy in monocotyledonous plants (monocots) such as maize and rice. Restricted to species that are vulnerable to Agrobacterium infection.

The possibility of suppressing genes and the impact of gene positioning on the expression of transgenes.

3.3 Biolistic particle delivery

It is a method used to deliver particles into cells or tissues by using a high-pressure helium gas to propel the particles.

Biolistic particle delivery, or the gene gun method, is a technique that involves the direct introduction of DNA into plant cells using high-speed microprojectiles. The procedure encompasses the subsequent stages:

1. DNA- Coated particles are prepared by applying DNA that encodes the gene of interest onto tiny gold or tungsten particles (32).

2. Particle Bombardment: The DNA-coated particles are propelled towards plant tissues using a gene gun, effectively piercing the cell walls and membranes.

3. Integration and Regeneration: The DNA becomes part of the plant's genetic material, and cells that have undergone transformation are carefully chosen and developed into complete plants (33).

Advantages: -

- Applicable to a diverse array of plant species, encompassing both dicots and monocots. Overcomes the constraints associated with Agrobacterium susceptibility.

- Enables the direct modification of chloroplast genomes, preventing the unintended spread of transgenes via pollen.

Disadvantages: -

- Reduced conversion efficiency in comparison to Agrobacterium-mediated techniques. There is a risk of tissue damage and the ability to regenerate is limited.

- Non-specific incorporation of transgenes can result in inconsistent amounts of gene expression and the suppression of gene activity (34).

3.4 Systems for the temporary production of proteins

Transient expression systems provide a fast alternative to stable transformation, allowing for the temporary and efficient production of recombinant proteins at high levels, without the requirement of integrating into the genome. These systems are especially valuable for efficiently generating proteins, such as in response to newly emerging diseases. Popular methods for temporary gene expression include the use of viral vectors and agroinfiltration.

3.5 Viral vectors

Plant viral vectors are genetically modified to transport and express genes from other organisms within plant cells (35). These vectors have the ability to invade plant cells and reproduce, resulting in significant amounts of production of recombinant proteins. Tobacco mosaic virus (TMV) and Cowpea mosaic virus (CPMV) are commonly used as viral vectors.

Advantages:-

- Efficient and expedited manufacturing of recombinant proteins within a short timeframe.

- Elevated levels of expression resulting from viral replication.

- Appropriate for mass production in industrial facilities.

Disadvantages:-

- Expression is limited in time, often lasting only a few weeks.

-There is a possibility of the rapid transmission of a virus and concerns regarding its impact on the environment (36).

-Restricted to proteins that do not hinder viral replication.

3.6 Agroinfiltration

Agroinfiltration is a technique that utilises Agrobacterium tumefaciens to temporarily transfer genes into plant cells (37). This method comprises the subsequent stages:

1. Culturing of Agrobacterium Strains: Agrobacterium strains containing the gene of interest are prepared.

2. Infiltration: The Agrobacterium suspension is introduced into plant tissues, usually leaves, through the use of a syringe or vacuum infiltration.

3. Gene Expression: The newly added genes exhibit a temporary period of activity, resulting in the production of the modified protein (38).

Advantages:-

- Quick and efficient production of genetically engineered proteins at a high level.

- Efficient and easily expandable procedure.

- Relevant to a diverse array of plant species.

Disadvantages:-

- Expression is ephemeral, usually enduring for a few weeks.

- Optimisation is necessary for each specific plant species and the protein being studied.

- There is a possibility of variation in the amounts of gene expression in various organs.

4. Optimization of Gene Expression

Maximising gene expression is a crucial element of molecular farming, guaranteeing the production of recombinant proteins at elevated levels and with the intended functionality (39). This section examines the several approaches employed to augment gene expression in plants, with a specific emphasis on promoters, enhancers, and terminators, codon optimisation, and subcellular targeting of recombinant proteins (40).

4.1 Promoters:

Promoters are particular DNA regions that initiate the process of transcription and are crucial in regulating the level and specificity of gene expression. The selection of a promoter is vital in order to attain elevated levels of expression for recombinant proteins in plants. Various types of promoters are utilised in molecular farming:

Constitutive promoters are responsible for maintaining uninterrupted gene expression in all tissues and during all phases of plant development. The Cauliflower mosaic virus (CaMV) 35S promoter is often utilised as a constitutive promoter owing to its robust and extensive functionality (41).

Tissue-specific promoters are responsible for regulating gene expression in particular tissues or organs, such as seeds, leaves, or roots. For instance, the seed-specific promoter derived from the phaseolin gene is employed to facilitate gene expression in seeds, hence promoting the stability and concentration of recombinant proteins in these tissues.

Inducible promoters are gene regulatory sequences that become active in response to certain environmental or chemical signals, enabling precise control over gene expression. A specific

instance is the ethanol-inducible promoter, which can be triggered by the administration of ethanol, allowing for accurate regulation of gene expression in terms of timing.

4.2 Enhancers:

Enhancers are specific DNA regions that enhance the transcriptional activity of promoters. These entities have the ability to operate in a manner that is not dependent on their position and can be found either before, after, or within the gene that they control. Enhancers function by promoting the interaction between transcription factors and the formation of the transcriptional apparatus (42). Utilising potent enhancers, such as the enhancer sequences derived from the CaMV 35S promoter, can greatly raise the levels of gene expression.

4.3 Terminators:

Terminators are specific sequences that serve as signals to indicate the completion of transcription. They play a crucial role in ensuring the stability and correct processing of mRNA. The nopaline synthase (NOS) terminator is commonly employed in plant transformation designs due to its high efficacy in facilitating transcription termination and polyadenylation of the mRNA (43). These processes are vital for maintaining mRNA stability and facilitating translation.

4.4 Codon optimization

It is the process of modifying the genetic code sequence in order to enhance the expression of a gene in a particular organism.

Codon optimisation entails altering the DNA sequence of the target gene to align with the host plant's preferred codon usage. Codon bias refers to the differing preferences of different organisms for specific codons that encode the same amino acid. Translation efficiency can be greatly enhanced by optimising codon use to match the quantity of tRNA in the host plant. This method encompasses the following:

Substituting infrequently utilised codons in the host plant with more commonly employed codons.

Preventing the formation of RNA secondary structures: Reducing sequences that have the potential to generate stable secondary structures in mRNA, which may impede the process of translation.

Preserving Amino Acid Sequence: Ensuring the protein's sequence of amino acids remains unaltered despite variations in the DNA sequence (44).

Codon optimisation can lead to increased protein expression, greater protein folding, and improved total output of recombinant proteins in plants.

4.5 Localization of Recombinant Proteins into Subcellular Compartments

Subcellular targeting of recombinant proteins includes directing them to specific compartments inside the plant cell, thereby improving their stability, accumulation, and usefulness. Distinct compartments offer distinct conditions that can enhance the synthesis of specific proteins.

Typical methods of targeting include:

Endoplasmic Reticulum (ER) Targeting: The ER creates a favourable environment for correct folding and post-translational modifications, such as glycosylation (45). Proteins can be directed to the endoplasmic reticulum (ER) by including a signal peptide at the N-terminus. Retention signals such as KDEL or HDEL can guarantee that proteins stay within the endoplasmic reticulum (ER), so avoiding their breakdown and improving their stability.

Chloroplast Targeting: Chloroplasts have the ability to collect substantial amounts of recombinant proteins as a result of their significant capacity for protein synthesis. Chloroplast targeting is accomplished by combining the gene of interest with a chloroplast transit peptide, which guides the protein to the chloroplast.

Vacuole Targeting: The vacuole functions as a storage organelle, and directing proteins to the vacuole can shield them from degradation in the cytoplasm (46). This is achieved by including vacuolar sorting signals within the protein.

Apoplast Targeting: The apoplast, also known as the extracellular space, can be utilised for the excretion of recombinant proteins. Proteins can be directed to the apoplast by including a signal peptide that guides secretion.

5. Downstream Processing and Purification

Downstream processing and purification are essential stages in molecular farming, with the goal of separating and purifying pharmaceuticals obtained from plants to meet the necessary requirements of purity, safety, and effectiveness (47). This section discusses the difficulties encountered in purifying medications generated from plants, as well as the latest advancements in purification methods. It also covers the precautions required to guarantee the safety and effectiveness of the final product.

5.1 Difficulties in the purification of pharmaceuticals generated from plants

Extracting medications from plant systems presents distinctive difficulties due to the intricate and varied nature of plant tissues. Some of the main difficulties are:

Plant tissues consist of many chemicals, including secondary metabolites, pigments, phenolics, and polysaccharides (48). These components can hinder the extraction and purification process of the desired recombinant protein.

Protease Activity:

Plants possess endogenous proteolytic enzymes that can break down recombinant proteins during the process of extraction and purification, resulting in decreased yield and compromising the integrity of the final product.

Protein expression can exhibit variability between plant species, tissues, and even within various regions of the same plant, which makes it challenging to establish standardised purification techniques

Scalability:

The task of expanding purifying procedures from a laboratory setting to an industrial scale, while ensuring consistency and efficiency, is particularly difficult for proteins that are produced in limited quantities.

Regulatory Compliance:

To guarantee that plant-derived pharmaceuticals adhere to strict regulatory criteria regarding their purity, safety, and effectiveness, it is necessary to implement strong and validated purification procedures.

5.2 Progress in Purification Methods

Affinity Chromatography: It is a method that takes advantage of the precise binding affinity between a desired protein and a ligand that is fixed to a chromatography matrix (49). One way to purify His-tagged proteins is by utilising affinity resins that have nickel or cobalt. Affinity chromatography provides a high level of specificity and purity, making it well-suited for the initial capture and concentration of recombinant proteins.

Protein A/G Chromatography: It is a regularly employed method for monoclonal antibodies purification. These proteins have a unique affinity for the Fc region of antibodies, which allows for their targeted extraction from plant extracts.

Hydrophobic Interaction Chromatography (HIC): It is a technique that separates proteins by exploiting their hydrophobic properties. By adjusting the salt concentrations, it is possible to selectively remove recombinant proteins from the chromatography column, therefore efficiently eliminating hydrophilic contaminants.

Ion Exchange Chromatography (IEX): It is a technique that separates proteins by using their electrical charge. By manipulating the pH and ionic strength of the buffer solution, specific proteins can be specifically attached to and released from the ion exchange resin.

Size Exclusion Chromatography (SEC): It is a technique that separates proteins by their molecular size. This method is very valuable for eliminating clusters and refining proteins to a state of uniformity, guaranteeing constant quality of the final product.

Two-phase extraction: It is a technique that separates proteins by utilising aqueous two-phase systems, which consist of polymers like polyethylene glycol (PEG) and dextran (50). It has practical applications in the purification of huge quantities and can be integrated with other chromatographic methods to achieve higher levels of purity.

Utilising a membrane as the basis Methods: Ultrafiltration and microfiltration membranes are employed to concentrate and purify plant extracts. Recent advancements in membrane technology have enhanced the efficiency of these procedures, resulting in decreased processing time and increased yield.

5.3 Ensuring the safety and effectiveness of products

Validating and ensuring the safety and effectiveness of pharmaceuticals produced from plants requires the implementation of many levels of validation and quality control measures:

Good Manufacturing Practices (GMP) refer to a set of guidelines that must be followed to guarantee that production processes are standardised, controlled, and recorded. This encompasses rigorous regulations on the sourcing of raw materials, the use of equipment, and the maintenance of the industrial environment.

Purity and potency testing is conducted on purified medications to ensure their quality, strength, and stability. Quantification and verification of the target protein's identification are accomplished using analytical techniques such as high-performance liquid chromatography (HPLC), mass spectrometry, and enzyme-linked immunosorbent assay (ELISA) (51).

Contaminant Elimination: It is vital to ensure the elimination of plant-specific pollutants, such as endotoxins, alkaloids, and secondary metabolites. This process entails the utilisation of sophisticated filtration, chromatography, and purifying techniques specifically devised to eradicate contaminants.

Functional experiments are performed to validate the therapeutic effectiveness of the recombinant protein by assessing its bioactivity. This may involve doing in vitro binding experiments, performing cell-based activity assays, and carrying out in vivo efficacy investigations.

Regulatory approval is required for plant-derived medications, and this approval is granted by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) based on certain standards. This process entails thorough documentation, rigorous clinical studies, and meticulous safety evaluations.

6. Applications of Molecular Farming

Molecular farming provides a flexible and expandable system for manufacturing a diverse array of valuable medications, utilising the biological synthesis skills of plants (52). This section examines the main uses of molecular farming, which involve producing monoclonal antibodies, creating vaccines, synthesising therapeutic enzymes, and showcasing noteworthy examples like ZMapp for Ebola and plant-based influenza vaccines.

6.1 Manufacturing Monoclonal Antibodies

Monoclonal antibodies (mAbs) are precise therapeutic proteins that are employed to treat a range of ailments, such as cancer, autoimmune disorders, and infectious diseases. Molecular farming offers a cost-efficient and easily expandable option for manufacturing monoclonal antibodies (mAbs) in contrast to conventional mammalian cell cultures.

Benefits:

Cost-effectiveness: Plant systems provide the advantage of being able to be grown on a larger scale at a lower cost compared to mammalian cell cultures.

Safety: Plants do not host human infections, hence minimising the danger of contamination. Scalability: The capacity to achieve a large biomass yield and expand production in open fields or greenhouses.

Examples:

ZMapp is a combination of three monoclonal antibodies that are created in Nicotiana benthamiana, a plant related to tobacco. It is utilised for the treatment of Ebola virus infection.

ZMapp exhibited effectiveness in decreasing death among infected patients during the 2014 Ebola epidemic.

Plant-based methods have been employed to generate monoclonal antibodies that specifically target the influenza virus, providing a fast reaction to newly developing strains.

6.2 Vaccine development

Vaccinations play a vital role in limiting the spread of infectious illnesses, and molecular farming presents a viable method for generating vaccinations that are both safe and effective (53). Plant-derived vaccines can be rapidly and efficiently manufactured, making them highly suitable for addressing pandemics and outbreaks.

Benefits:

Swift Manufacturing: Transient expression methods facilitate the expedited manufacture of vaccines, a crucial factor during outbreaks.

Scalability: The ability to cultivate plants in huge quantities enables the efficient and extensive manufacture of vaccines.

Safety: Decreased likelihood of exposure to human diseases and other detrimental substances.

Illustrations: Plant-based influenza vaccines, such as those derived from Nicotiana benthamiana, have demonstrated effectiveness in clinical studies. These vaccines can be swiftly manufactured in response to emerging influenza viruses.

6.3 Production of Medicinal Enzymes

Therapeutic enzymes are employed for the treatment of many metabolic abnormalities and diseases. Molecular farming allows for the efficient and expandable manufacturing of these enzymes at a reasonable cost (54).

Benefits:

Cost Reduction: The utilisation of plants for enzyme manufacturing might substantially decrease production expenses in comparison to conventional approaches.

Scalability: Scalibility refers to the capacity to achieve high biomass yield and cultivate plants on a wide scale.

6.4 Illustrations:

Glucocerebrosidase, an enzyme utilised for the treatment of Gaucher's illness, has been successfully grown in carrot cells using molecular farming techniques. Clinical testing have shown that it is both effective and safe.

Alpha-galactosidase, an enzyme utilised for the management of Fabry disease, has been effectively synthesised in tobacco plants (55).

7. Regulatory and Public Perception Challenges

Nanotechnology in medicine delivery encounters several regulatory and public perception obstacles during its development and deployment. These obstacles can have a substantial effect on the advancement and adoption of nanotechnology-based solutions.

The regulatory framework for nanotechnology in drug delivery is intricate and continuously developing. The FDA (Food and Drug Administration) in the United States and the EMA (European Medicines Agency) in Europe are regulatory authorities that have a vital role in establishing criteria and rules for approving nanomedicines (56). These laws guarantee the safety, effectiveness, and quality of pharmaceuticals that are based on nanotechnology.

1. Safety and Efficacy Evaluation:

Regulatory authorities want extensive data regarding the safety and effectiveness of nanomedicines. This encompasses preclinical investigations, clinical trials, and post-market monitoring. Specialised testing techniques are required due to the distinctive characteristics of nanoparticles, including their size, surface area, and reactivity.

2. Manufacturing Standards:

The manufacturing of nanomedicines must strictly comply with rigorous Good Manufacturing Practices (GMP). This involves guaranteeing the uniformity and integrity of the nanomaterials employed. Regulatory bodies conduct inspections of manufacturing plants to verify adherence to these criteria.

3. Labelling and transparency:

It is crucial for clearly indicating the use of nanomaterials in medication formulations (57). This fosters the development of trust between healthcare personnel and patients.

4. Standardisation of rules:

It is necessary to standardise rules across various countries in order to promote global trade and cooperation in nanomedicine research. Discrepancies in regulatory mandates can impede the progress and marketability of pharmaceuticals based on nanotechnology.

7.2 Perception and Acceptance of Genetically Modified Organisms (GMOs) by the Public

The adoption and success of nanotechnology, particularly in drug delivery, can be greatly influenced by the way it is seen and accepted by the public. Public opinion can be influenced by concerns of safety, ethical consequences, and environmental effect.

1. Safety Concerns: Public apprehensions over the potential toxicity and enduring consequences of nanoparticles can impede acceptance. Ensuring clear and open communication of scientific evidence that proves the safety of nanomedicines is essential in resolving these concerns.

2. Ethical Implications: The utilisation of nanotechnology in medicine raises ethical concerns that must be acknowledged, including matters of privacy, informed consent, and the possibility of misuse. Public engagement and conversation can facilitate the comprehension and alleviation of these challenges.

3. Education and Awareness: Enhancing public knowledge and comprehension of the advantages and potential drawbacks of nanotechnology in pharmaceutical delivery might facilitate the process of acquiring approval and support. Education campaigns and outreach programmes are crucial in this context.

4. Confidence in Regulatory Bodies: The confidence of the public in regulatory bodies and their capacity to guarantee the safety and effectiveness of nanomedicines is of utmost importance (58). Public confidence can be improved by implementing transparent and efficient regulatory mechanisms.

7.3 Issues related to intellectual property and the process of commercialising intellectual property.

The presence of intellectual property (IP) rights and the difficulties associated with commercialization pose substantial obstacles in the advancement and implementation of drug delivery systems based on nanotechnology.

1. Patent Protection: Obtaining patents for discoveries based on nanotechnology is essential for safeguarding intellectual property. Nevertheless, the newness and intricacy of nanotechnology can pose difficulties when filing for patents. Explicit criteria and assistance for obtaining patents for nanoscale innovations are crucial.

2. Licencing and Technology Transfer: Efficient licencing agreements and processes for technology transfer are essential for the successful transition of nanomedicines from the laboratory to the market (59). Cooperation among academic institutions, research organisations, and pharmaceutical businesses can expedite this process.

3. Market Competition: The presence of competitors in the pharmaceutical sector can affect the process of bringing nanomedicines to the market. Forming strategic alliances and collaborations can assist in effectively navigating the competitive landscape and attaining success in the market.

4. Cost and Accessibility: The exorbitant expenses associated with the development and

production of nanomedicines can restrict their availability to a wider population. It is essential to make significant efforts in order to decrease expenses and guarantee fair availability of these modern treatments, since this is vital for their general acceptance and use.

To ensure the successful integration of nanotechnology in drug delivery, it is crucial to tackle the regulatory, public perception, and commercialization problems associated with it. The cooperation of scientists, regulatory organisations, industry stakeholders, and the public can facilitate the development of novel and efficient nanomedicines.

8. Economic and Scalability Considerations:

The economic feasibility and ability to expand of molecular agricultural systems are essential considerations in determining their future acceptance and achievement (60). These factors impact the feasibility and practicality of producing high-value medications produced from plants on a large scale, as compared to traditional techniques of pharmaceutical production.

8.1 Economic efficiency of plant-based production

Plant-based production techniques provide numerous cost benefits compared to conventional methods:

1. Reduced Production Costs: Utilizing plants as biofactories for pharmaceuticals can offer a substantial cost advantage compared to conventional cell culture or microbial fermentation systems. Plants necessitate a reduced number of costly inputs, such as growing medium, fertilisers, and controlled environmental conditions.

2. Decreased Capital Expenditure: The infrastructure necessary for plant-based production, such as greenhouses or open fields, is typically less expensive than the advanced bioreactors and facilities required for microbial or mammalian cell cultures.

3. Scalability and Flexibility: Plants can be cultivated on a significant scale with relative simplicity, and the production capacity can be modified by expanding the cultivation area. This scalability offers significant benefits when it comes to addressing high demand or rapidly increasing production in response to pandemics or other pressing requirements.

4. Reduced Operational Expenses: Plant-based systems often incur lower operational expenses, encompassing labour, energy, and maintenance (61). In addition, plants can be genetically modified to directly produce the desired product, reducing the need for subsequent processing and purifying stages.

5. Sustainability: Plant-based systems exhibit greater sustainability and environmental friendliness, hence decreasing the carbon footprint linked to pharmaceutical manufacturing. This

sustainability can result in financial savings and be in line with the growing requirements of regulations and consumers for more environmentally friendly production practices.

8.2 The scalability of molecular farming systems.

The commercial success of molecular farming heavily relies on scalability.

1. Agricultural Expansion: The cultivation of plants on agricultural land enables a substantial increase in output capacity. Contemporary agricultural methods, such as precision farming, have the potential to maximise crop production and enhance efficiency.

2. Greenhouse and Vertical Farming: Controlled environment agriculture, such as greenhouses and vertical farms, allows for continuous production throughout the year, regardless of weather conditions (62). These systems have the capability to be expanded vertically, which allows for optimal use of space and increased production productivity.

3. Genetic stability and yield consistency: These are essential factors for achieving scalability in the production of pharmaceutical compounds. It is important to ensure that the desired compounds are consistently produced across successive generations of plants. Progress in plant breeding and genetic engineering can assist in accomplishing these objectives.

4. Harvesting and processing: These are crucial for expanding plant-based output. It is imperative to employ efficient procedures in order to scale up production. Implementing mechanised harvesting and automated processing technologies can enhance operational efficiency and decrease labour expenses.

5. Regulatory Compliance: Expanding molecular farming systems requires adhering to regulatory frameworks to guarantee compliance with safety, quality, and environmental norms. Efficient regulatory procedures can help smooth the shift from small-scale testing to large-scale manufacturing.

8.3 Contrast with Conventional Methods of Pharmaceutical Production

When contrasting plant-based molecular farming with conventional pharmaceutical production methods, certain crucial variables come into consideration:

1. Production Efficiency: Conventional techniques, such as microbial fermentation and mammalian cell cultures, provide optimal production efficiency and high yield of intricate compounds (63). Nevertheless, the utilisation of bioreactors, media, and controlled conditions necessitates substantial financial resources.

2. Cost Implications: Although traditional methods can generate significant outputs, they frequently entail increased expenditures for raw materials, infrastructure, and operational costs.

Conversely, plant-based systems can achieve comparable yields while incurring far lower expenses.

3. Rapid Time to Market: Conventional approaches may offer speedier development and production cycles as a result of well-established procedures and regulatory expertise. Plant-based systems may necessitate additional time for optimisation and expansion, while advancements in genetic engineering and agricultural techniques are diminishing these timeframes.

4. Product Purity and Quality: Maintaining a high level of purity and quality in medicines is of utmost importance. Conventional techniques provide accurate management of production conditions, leading to constant product quality. Plant-based systems must confront issues associated with the variability in plant growth and the extraction of compounds.

5. Regulatory Acceptance: Conventional pharmaceutical manufacturing techniques are firmly established and have clearly defined regulatory routes. Plant-based solutions are very recent and might encounter more rigorous examination and lengthier clearance processes as regulatory agencies adjust to these groundbreaking methods.

6. Environmental Impact: Conventional technologies exhibit a greater environmental imprint as a result of energy-intensive procedures and the production of waste. Plant-based systems are characterised by their higher sustainability and their ability to provide a greener alternative with a reduced environmental footprint.

9. Future Prospects and Innovations

The potential of molecular farming is highly promising as ongoing advancements in technology and creativity propel the industry forward. These advancements possess the capacity to tackle worldwide health obstacles and open up opportunities for novel study avenues and cooperative endeavours.

9.1 Advancements in Molecular Farming Technologies

Multiple state-of-the-art technologies are ready to completely transform molecular farming:

1. CRISPR and Gene Editing: CRISPR-Cas9 and other gene-editing techniques allow for accurate alterations to the genetic makeup of plants (64). This enables the precise incorporation or improvement of genes responsible for synthesising medicinal molecules, so enhancing both productivity and effectiveness.

2. Synthetic biology: It is the field that focuses on the deliberate creation and assembly of novel biological components, mechanisms, and structures. Synthetic biology can be employed in

molecular farming to design efficient pathways for the synthesis of intricate molecules, thereby augmenting the capacity of plants to function as biofactories.

3. Advanced plant breeding methods: Such as marker-assisted selection and genomic selection, expedite the creation of plant varieties that have high productivity, resistance to diseases, and tolerance to stressful conditions. These developments enhance the overall efficiency and dependability of molecular agricultural systems.

4.Metabolic engineering: It is a field that involves altering the metabolic pathways of plants in order to enhance the synthesis of specific chemicals. Through the optimisation of these pathways, scientists can improve the effectiveness and output of pharmaceutical manufacture in plants.

5. Nanotechnology: It can be utilised in molecular farming to enhance the transportation and durability of synthesised chemicals. Nanocarriers have the capacity to safeguard delicate molecules, improve their availability in biological systems, and facilitate precise transportation to particular tissues or cells.

Automation and precision agriculture are advanced technologies that can optimise the cultivation, harvesting, and processing of pharmaceutical plants. These technologies include robotic harvesting and precise agricultural techniques. These advancements enhance productivity, decrease labour expenses, and guarantee uniformity in product excellence.

9.2 Potential for Tackling Global Health Issues

Molecular farming offers the possibility to tackle numerous global health issues by offering economical and scalable methods for manufacturing crucial medications.

1. Vaccine Production: Utilizing plant-based systems enables the quick and cost-effective production of vaccinations, hence increasing accessibility for low-income countries. This strategy is of utmost importance during pandemics, as it allows for the rapid manufacturing and dissemination of vaccinations.

2. Therapeutic Proteins and Antibodies: Plants can be genetically modified to synthesise therapeutic proteins and monoclonal antibodies that are utilised in the medical treatment of various ailments, including cancer, autoimmune disorders, and infectious diseases. These biologics derived from plants can be manufactured at a lower cost and in greater quantities.

3. Molecular farming: It has the capability to generate nutraceuticals and functional foods that are fortified with vitamins, minerals, and bioactive substances. These items have the potential to mitigate malnutrition and enhance the general well-being of susceptible populations.

4. Enhancing Global Supply Chain Resilience: Molecular farming can strengthen the resilience of global supply chains by dispersing pharmaceutical production and utilising local agricultural resources. This approach reduces reliance on centralised manufacturing facilities and helps mitigate the effects of supply chain disruptions.

9.3 Prospects for Future Research and Opportunities for Collaboration

In order to fully harness the potential of molecular farming, it is imperative to pursue various research avenues and foster joint endeavours.

1. Enhancing Expression Systems Optimization: Research should prioritise the enhancement of plant expression systems to maximise the production, stability, and effectiveness of medicinal chemicals. This involves the creation of novel promoters, enhancers, and regulatory components.

2. Enhancing Downstream Processing: Advancements in downstream processing methods, including purification and formulation, are essential for guaranteeing the purity and effectiveness of medications generated from plants. It is crucial to develop purifying processes that are both cost-effective and scalable.

3. Resolving Regulatory Challenges: To ensure consistency and clarity in the regulation of plant-based pharmaceuticals, it is imperative for scientists, regulatory agencies, and industry stakeholders to work together collaboratively (65). This involves establishing criteria for evaluating the safety, effectiveness, and quality of a product or service.

4. Public Engagement and Education: It is crucial to actively include the public and provide them with information about the advantages and security of molecular farming in order to obtain acceptance and establish trust. Effective and transparent communication and outreach initiatives can help to clarify misunderstandings and garner backing.

5. Interdisciplinary Collaboration: Collaboration among many fields such as plant science, biotechnology, pharmacology, and engineering can foster innovation in molecular farming. Interdisciplinary research teams have the ability to tackle intricate difficulties and create comprehensive solutions.

6. International collaborations: Creating worldwide alliances and networks can enable the exchange of knowledge, transfer of technology, and development of capabilities. Cooperative endeavours can facilitate the expansion of molecular farming projects and guarantee fair and equal availability of plant-based medications on a global scale.

10. Conclusion

The investigation of molecular farming as an innovative method for manufacturing valuable medications derived from plants has brought attention to notable progress and prospects in the sector. This conclusion consolidates the main discoveries, examines the consequences for the pharmaceutical sector, and outlines a perspective for the future of molecular farming.

10.1 Key findings summary

1. Molecular farming provides a financially efficient and easily expandable option as compared to conventional techniques of pharmaceutical production. The use of plant-based systems is highly tempting due to their lower manufacturing costs, reduced capital expenditure, and scalability.

2. The effective execution of molecular farming necessitates traversing intricate regulatory frameworks and addressing concerns regarding public perception. It is essential to prioritise safety, effectiveness, and openness in order to obtain regulatory approval and earn public acceptability.

3. Technological advancements, including CRISPR, synthetic biology, enhanced plant breeding, metabolic engineering, nanotechnology, and automation, are propelling the development of molecular farming. These advancements improve the effectiveness, productivity, and excellence of medications generated from plants.

4. Molecular farming has substantial potential to tackle global health issues such as vaccine manufacturing, production of therapeutic proteins and antibodies, development of nutraceuticals, and creation of remedies for rare diseases. The capacity to generate cost-effective and expandable pharmaceuticals has the potential to enhance the availability of vital medications.

5. Ongoing research and interdisciplinary collaboration are crucial for maximising the efficiency of expression systems, enhancing downstream processing, tackling regulatory obstacles, and actively involving the public. Global collaborations can enhance the exchange of knowledge and transfer of technologies.

10.2 Implications for the Pharmaceutical Industry

1. Cost Reduction: Utilising plant-based production methods can result in substantial savings in the pharmaceutical manufacturing process due to its cost-effectiveness. This has the potential to enhance the affordability and availability of pharmaceuticals, particularly in economically disadvantaged areas.

2. Production Flexibility: The ability to scale up and adapt quickly in molecular farming enables rapid changes in production capacity. During health emergencies, the ability to quickly produce vaccinations and treatments can be highly advantageous.

3. Sustainability: Plant-based production techniques provide a more sustainable and ecologically conscious alternative to conventional approaches. Minimising the environmental impact of pharmaceutical manufacture is in line with the growing requirements from both regulators and consumers for eco-friendly production methods.

4. Innovation and Competition: Molecular farming is a groundbreaking innovation that is causing significant changes in the pharmaceutical business. Businesses who allocate resources to and embrace this technology have the potential to gain a competitive advantage by providing innovative medications produced from plants.

5. Regulatory Adaptation: The pharmaceutical industry must collaborate closely with regulatory organisations to establish and standardise protocols for the authorization of plant-derived medications. Cooperative endeavours can optimise the regulatory procedure and expedite market access.

10.3 Future Prospects of Molecular Farming

The future of molecular farming is promising, with various crucial factors influencing its advancement:

1. Incorporation of Cutting-Edge Technologies: The ongoing incorporation of cutting-edge technologies, including as gene editing, synthetic biology, and automation, will improve the efficiency and capabilities of molecular farming systems.

2. Global Collaboration: International cooperation and alliances will be essential for expanding molecular farming projects and guaranteeing fair availability of medications generated from plants. Sharing knowledge and transferring technology helps expedite advancement and tackle worldwide health inequalities.

3. Public Engagement and Education: Establishing public confidence and approval by means of open and informative communication is crucial. Interacting with communities and stakeholders helps cultivate a conducive atmosphere for the acceptance and implementation of molecular farming.

4. Regulatory Frameworks: Establishing unambiguous, uniform, and synchronised regulatory frameworks will be crucial for the commercialization of plant-derived medications. Regulatory organisations should collaborate with industry and researchers to develop rules that guarantee both safety and effectiveness, while also promoting innovation.

Implementing sustainable techniques in molecular farming will help create a more

environmentally friendly pharmaceutical sector. This encompasses the enhancement of resource utilisation, the reduction of waste, and the minimization of the ecological consequences of manufacturing procedures.

To summarise, molecular farming is a revolutionary method for manufacturing pharmaceuticals, providing cost-effective, scalable, and environmentally friendly options for creating valuable medications derived from plants. The progress in technology, capacity to tackle worldwide health issues, and cooperative endeavours are propelling the field ahead. Through ongoing innovation and strategic collaborations, molecular farming has the capacity to transform the pharmaceutical sector and enhance global health results.

11. Refrences

Abiri, R., Valdiani, A., Maziah, M., Shaharuddin, N. A., Sahebi, M., Yusof, Z. N. B., ... & Talei, D. (2016). A critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming. Current Issues in Molecular Biology, 18(1), 21-42.

Sharma, A. K., & Sharma, M. K. (2009). Plants as bioreactors: recent developments and emerging opportunities. Biotechnology advances, 27(6), 811-832.

Nikiema, J., & Asiedu, Z. (2022). A review of the cost and effectiveness of solutions to address plastic pollution. Environmental Science and Pollution Research, 29(17), 24547-24573.

Park, K. Y., & Wi, S. J. (2016). Potential of plants to produce recombinant protein products. Journal of Plant Biology, 59, 559-568.

Basaran, P., & Rodríguez-Cerezo, E. (2008). Plant molecular farming: opportunities and challenges. Critical reviews in biotechnology, 28(3), 153-172.

Sticklen, M. B. (2008). Plant genetic engineering for biofuel production: towards affordable cellulosic ethanol. Nature reviews genetics, 9(6), 433-443.

Campos, M. L., Prado, G. S., Dos Santos, V. O., Nascimento, L. C., Dohms, S. M., da Cunha, N. B., ... & Dias, S. C. (2020). Mosses: versatile plants for biotechnological applications. Biotechnology Advances, 41, 107533.

Abiri, R., Valdiani, A., Maziah, M., Shaharuddin, N. A., Sahebi, M., Yusof, Z. N. B., ... & Talei, D. (2016). A critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming. Current Issues in Molecular Biology, 18(1), 21-42.

Komarova, T. V., Baschieri, S., Donini, M., Marusic, C., Benvenuto, E., & Dorokhov, Y. L. (2010). Transient expression systems for plant-derived biopharmaceuticals. Expert review of vaccines, 9(8), 859-876.

Papaneophytou, C. P., & Kontopidis, G. (2014). Statistical approaches to maximize recombinant protein expression in Escherichia coli: a general review. Protein expression and purification, 94, 22-32.

Leavitt, J. M., & Alper, H. S. (2015). Advances and current limitations in transcript-level control of gene expression. Current opinion in biotechnology, 34, 98-104.

Bhatia, S., & Dahiya, R. (2015). Plant-based biotechnological products with their production host, modes of delivery systems, and stability testing (pp. 293-331). Cambridge, MA: Academic Press.

Brown, E., Dessai, U., McGarry, S., & Gerner-Smidt, P. (2019). Use of whole-genome sequencing for food safety and public health in the United States. Foodborne pathogens and disease, 16(7), 441-450.

Zeghibe, A. C. (2021). Growing Into Their Own?: Plant Molecular Farming and the Pursuit of Biotechnological Sovereignty for Lower and Middle Income Countries (Doctoral dissertation, Wellesley College).

Spök, A., Twyman, R. M., Fischer, R., Ma, J. K., & Sparrow, P. A. (2008). Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants. Trends in Biotechnology, 26(9), 506-517.

Ricroch, A., Harwood, W., Svobodová, Z., Sági, L., Hundleby, P., Badea, E. M., ... & Kuntz, M. (2016). Challenges facing European agriculture and possible biotechnological solutions. Critical reviews in biotechnology, 36(5), 875-883.

Zamora-Ledezma, C., Medina, E., Sinche, F., Santiago Vispo, N., Dahoumane, S. A., & Alexis, F. (2020). Biomedical science to tackle the COVID-19 pandemic: current status and future perspectives. Molecules, 25(20), 4620.

Abiri, R., Valdiani, A., Maziah, M., Shaharuddin, N. A., Sahebi, M., Yusof, Z. N. B., ... & Talei, D. (2016). A critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming. Current Issues in Molecular Biology, 18(1), 21-42.

Yeh, N., & Chung, J. P. (2009). High-brightness LEDs—Energy efficient lighting sources and their potential in indoor plant cultivation. Renewable and Sustainable Energy Reviews, 13(8), 2175-2180.

Roderick, G. K., & Navajas, M. (2003). Genes in new environments: genetics and evolution in biological control. Nature Reviews Genetics, 4(11), 889-899.

Webster, D. E., & Thomas, M. C. (2012). Post-translational modification of plant-made foreign proteins; glycosylation and beyond. Biotechnology Advances, 30(2), 410-418.

Shaw, I. C. (2018). Food safety: the science of keeping food safe. John Wiley & Sons.
Benedetti, M., Vecchi, V., Barera, S., & Dall'Osto, L. (2018). Biomass from microalgae: the potential of domestication towards sustainable biofactories. Microbial Cell Factories, 17, 1-18.

Schröder, P., Beckers, B., Daniels, S., Gnädinger, F., Maestri, E., Marmiroli, N., ... & Sæbø, A. (2018). Intensify production, transform biomass to energy and novel goods and protect soils in Europe—A vision how to mobilize marginal lands. Science of the Total Environment, 616, 1101-1123.

National Research Council, Division on Earth, Life Studies, & Committee on Twenty-First Century Systems Agriculture. (2010). Toward sustainable agricultural systems in the 21st century. National Academies Press.

Schaefer, D. G. (2002). A new moss genetics: targeted mutagenesis in Physcomitrella patens. Annual review of plant biology, 53(1), 477-501.

Kusnadi, A. R., Nikolov, Z. L., & Howard, J. A. (1997). Production of recombinant proteins in transgenic plants: practical considerations. Biotechnology and bioengineering, 56(5), 473-484.

Niklas, K. J., Bondos, S. E., Dunker, A. K., & Newman, S. A. (2015). Rethinking gene regulatory networks in light of alternative splicing, intrinsically disordered protein domains, and post-translational modifications. Frontiers in cell and developmental biology, 3, 8.

Abiri, R., Valdiani, A., Maziah, M., Shaharuddin, N. A., Sahebi, M., Yusof, Z. N. B., ... & Talei, D. (2016). A critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming. Current Issues in Molecular Biology, 18(1), 21-42.

Zatyka, M., & Thomas, C. M. (1998). Control of genes for conjugative transfer of plasmids and other mobile elements. FEMS microbiology reviews, 21(4), 291-319.

Birch, R. G. (1997). Plant transformation: problems and strategies for practical application. Annual review of plant biology, 48(1), 297-326.

Finer, J. J., Vain, P., Jones, M. W., & McMullen, M. D. (1992). Development of the particle inflow gun for DNA delivery to plant cells. Plant cell reports, 11, 323-328.

Fraley, R. T., Rogers, S. G., Horsch, R. B., & Gelvin, S. B. (1986). Genetic transformation in higher plants. Critical reviews in plant sciences, 4(1), 1-46.

Collon, K., Gallo, M. C., & Lieberman, J. R. (2021). Musculoskeletal tissue engineering: Regional gene therapy for bone repair. Biomaterials, 275, 120901.
Lico, C., Chen, Q., & Santi, L. (2008). Viral vectors for production of recombinant proteins in plants. Journal of cellular physiology, 216(2), 366-377.

Sharma, G. D., Tiwari, A. K., Jain, M., Yadav, A., & Srivastava, M. (2021). COVID-19 and environmental concerns: A rapid review. Renewable and Sustainable Energy Reviews, 148, 111239.

Kaur, M., Manchanda, P., Kalia, A., Ahmed, F. K., Nepovimova, E., Kuca, K., & Abd-Elsalam, K. A. (2021). Agroinfiltration mediated scalable transient gene expression in genome edited crop plants. International Journal of Molecular Sciences, 22(19), 10882.

Andersen, J. B., Sternberg, C., Poulsen, L. K., Bjørn, S. P., Givskov, M., & Molin, S. (1998). New unstable variants of green fluorescent protein for studies of transient gene expression in bacteria. Applied and environmental microbiology, 64(6), 2240-2246.

Jamal, A., Ko, K., Kim, H. S., Choo, Y. K., Joung, H., & Ko, K. (2009). Role of genetic factors and environmental conditions in recombinant protein production for molecular farming. Biotechnology Advances, 27(6), 914-923.

Biłas, R., Szafran, K., Hnatuszko-Konka, K., & Kononowicz, A. K. (2016). Cis-regulatory elements used to control gene expression in plants. Plant Cell, Tissue and Organ Culture (PCTOC), 127, 269-287.

Turner, D. S., McCallum, D. G., & Covey, S. N. (1996). Roles of the 35S promoter and multiple overlapping domains in the pathogenicity of the pararetrovirus cauliflower mosaic virus. Journal of virology, 70(8), 5414-5421.

Grossman, S. R., Zhang, X., Wang, L., Engreitz, J., Melnikov, A., Rogov, P., ... & Lander, E. S. (2017). Systematic dissection of genomic features determining transcription factor binding and enhancer function. Proceedings of the National Academy of Sciences, 114(7), E1291-E1300.

F de Felippes, F., McHale, M., Doran, R. L., Roden, S., Eamens, A. L., Finnegan, E. J., & Waterhouse, P. M. (2020). The key role of terminators on the expression and post-transcriptional gene silencing of transgenes. The Plant Journal, 104(1), 96-112.

Pearson, W. R., Wood, T., Zhang, Z., & Miller, W. (1997). Comparison of DNA sequences with protein sequences. Genomics, 46(1), 24-36.

Ellgaard, L., McCaul, N., Chatsisvili, A., & Braakman, I. (2016). Co-and post-translational protein folding in the ER. Traffic, 17(6), 615-638.
Tan, X., Li, K., Wang, Z., Zhu, K., Tan, X., & Cao, J. (2019). A review of plant vacuoles: formation, located proteins, and functions. Plants, 8(9), 327.

Drossard, J. (2004). Downstream processing of plant-derived recombinant therapeutic proteins. Molecular Farming: Plant-made Pharmaceuticals and Technical Proteins, 217-231.

Kandar, C. C. (2021). Secondary metabolites from plant sources. Bioactive natural products for pharmaceutical applications, 329-377.

Azarkan, M., Huet, J., Baeyens-Volant, D., Looze, Y., & Vandenbussche, G. (2007). Affinity chromatography: a useful tool in proteomics studies. Journal of Chromatography B, 849(1-2), 81-90.

Singla, M., & Sit, N. (2023). Theoretical Aspects and Applications of Aqueous Two-Phase Systems. ChemBioEng Reviews, 10(1), 65-80.

Pan, S., Aebersold, R., Chen, R., Rush, J., Goodlett, D. R., McIntosh, M. W., ... & Brentnall, T. A. (2009). Mass spectrometry based targeted protein quantification: methods and applications. Journal of proteome research, 8(2), 787-797.

Massa, S., Presenti, O., & Benvenuto, E. (2019). Engineering plants for the future: farming with value-added harvest. Progress in Botany Vol. 80, 65-108.

Chung, Y. H., Church, D., Koellhoffer, E. C., Osota, E., Shukla, S., Rybicki, E. P., ... & Steinmetz, N. F. (2022). Integrating plant molecular farming and materials research for next-generation vaccines. Nature Reviews Materials, 7(5), 372-388.

Fischer, R., & Buyel, J. F. (2020). Molecular farming–the slope of enlightenment. Biotechnology advances, 40, 107519.

Yusibov, V., Kushnir, N., & Streatfield, S. J. (2015). Advances and challenges in the development and production of effective plant-based influenza vaccines. Expert review of vaccines, 14(4), 519-535.

Gray, G. C., & Silbey, S. S. (2014). Governing inside the organization: Interpreting regulation and compliance. American Journal of Sociology, 120(1), 96-145.

Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufès, C., ... & Pastore, C. (2019). On the issue of transparency and reproducibility in nanomedicine. Nature nanotechnology, 14(7), 629-635.

Halwani, A. A. (2022). Development of pharmaceutical nanomedicines: from the bench to the market. Pharmaceutics, 14(1), 106.

Allan, J. E., Ferreri, A., Grande, S., Giannantonio, R., & Matteucci, F. (2019). Technology transfer in nanotechnology. Publications Office of the European Union, Luxembourg.

Basaran, P., & Rodríguez-Cerezo, E. (2008). Plant molecular farming: opportunities and challenges. Critical reviews in biotechnology, 28(3), 153-172.

Sadhukhan, J., Dugmore, T. I., Matharu, A., Martinez-Hernandez, E., Aburto, J., Rahman, P. K., & Lynch, J. (2020). Perspectives on "game changer" global challenges for sustainable 21st century: plant-based diet, unavoidable food waste biorefining, and circular economy. Sustainability, 12(5), 1976.

Mitchell, C. A. (2022). History of controlled environment horticulture: Indoor farming and its key technologies. HortScience, 57(2), 247-256.

Gupta, S. K., & Shukla, P. (2017). Sophisticated cloning, fermentation, and purification technologies for an enhanced therapeutic protein production: a review. Frontiers in pharmacology, 8, 274690.

Van Eck, J. (2020). Applying gene editing to tailor precise genetic modifications in plants. Journal of Biological Chemistry, 295(38), 13267-13276.

Lewis, B. W. (2022). Risk, Regulation and Strategy: A Multi-Case Study of the Botanical Drug Industry (Doctoral dissertation, ResearchSpace@ Auckland).